Document:

Sales Agreement, dated August 11, 2011

 Exhibit 10.1 
 SUNESIS PHARMACEUTICALS, INC. 
 $20,000,000 of Common Stock

 (par value $0.0001 per share) 

Controlled Equity OfferingSM 
 Sales Agreement 
 August 11, 2011 

CANTOR FITZGERALD & CO. 
 499 Park
Avenue 
 New York, NY 10022 
 Ladies
and Gentlemen: 
 SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), confirms its
agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“CF&Co”), as follows: 
 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell
through CF&Co, acting as agent and/or principal, shares (the “Placement Shares”) of the Company’s common stock par value $0.0001 per share (the “Common Stock”) up to an aggregate offering
price of $20,000,000, subject to Section 6(e) hereof (the “Maximum Amount”). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in
this Section 1 on the number of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and CF&Co shall have no obligation in connection with such compliance, provided that CF&Co
strictly follows the trading instructions provided pursuant to any Placement Notice. The issuance and sale of Placement Shares through CF&Co will be effected pursuant to the Registration Statements (as defined below) filed by the Company and
declared effective by the Securities and Exchange Commission (the “Commission”), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statements (as defined below) to issue
Common Stock. 
 The Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder (collectively, the “Securities Act”), with the Commission Registration Statements on Form S-3 (Nos. 333-164025 and 333-166366), each including a base prospectus, relating to
certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporate by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”). The Company has prepared a prospectus supplement to the base prospectuses included as part of such registration
statements specifically relating to the Placement Shares (the “Prospectus Supplement”). The Company will furnish to 

  
 1 

 
CF&Co, for use by CF&Co, copies of the prospectuses included as part of such registration statements, as supplemented by the Prospectus Supplement, relating to the Placement Shares.
Except where the context otherwise requires, such registration statements, as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a
Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statements pursuant to Rule 430B or 462(b) of the Securities Act, as well as any
comparable successor registration statement filed by the Company for the sale of shares of its Common Stock, including the Placement Shares, collectively are herein called the “Registration Statements.” The base prospectuses,
including all documents incorporated therein by reference, included in the Registration Statements, as each may be supplemented by the Prospectus Supplement, in the form in which such prospectuses and/or Prospectus Supplement have most recently been
filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with the then issued Issuer Free Writing Prospectus(es), is herein called the “Prospectus.” Any reference herein to the
Registration Statements, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms “amend,” “amendment” or
“supplement” with respect to the Registration Statements or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein
(the “Incorporated Documents”). For purposes of this Agreement, all references to the Registration Statements, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the
Commission pursuant to either the Electronic Data Gathering Analysis and Retrieval System or Interactive Data Electronic Applications (collectively “IDEA”). 

2. Placements. Each time that the Company wishes to issue and sell the Placement Shares hereunder (each, a
“Placement”), it will notify CF&Co by email notice (or other method mutually agreed to in writing by the parties) (a “Placement Notice”) containing the parameters in accordance with which it
desires the Placement Shares to be sold, which shall at a minimum include the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement Shares that may be sold in
any one Trading Day (as defined in Section 3) and any minimum price below which sales may not be made, a form of which containing such minimum sales parameters necessary is attached hereto as Schedule 1. The Placement Notice shall
originate from any of the individuals from the Company set forth on Schedule 2 (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from CF&Co
set forth on Schedule 2, as such Schedule 2 may be amended from time to time. The Placement Notice shall be effective upon receipt by CF&Co unless and until (i) in accordance with the notice requirements set
forth in Section 4, CF&Co declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of the Placement Shares, either under this Agreement or pursuant to a Placement Notice, have been
sold, (iii) in accordance with the notice requirements set forth in Section 4, the Company suspends or terminates the Placement Notice, (iv) the Company issues a subsequent Placement Notice with parameters superseding those on the
earlier dated Placement Notice, (v) CF&Co declines to continue to make sales under an existing Placement Notice, for any reason, in its sole discretion, or (vi) this Agreement has been terminated under the provisions of
Section 11. The amount of any discount, commission or other compensation to be paid by the Company to CF&Co in 

  
 2 

 
connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in Schedule 3. It is expressly acknowledged and agreed that neither the
Company nor CF&Co will have any obligation whatsoever with respect to a Placement Notice or any Placement Shares unless and until the Company delivers a Placement Notice to CF&Co and CF&Co does not decline such Placement Notice pursuant
to the terms set forth above, and then only upon the terms specified therein and herein. 
 3. Sale of Placement Shares
by CF&Co. Subject to the terms and conditions herein set forth, upon the Company’s issuance of a Placement Notice, and unless the sale of the Placement Shares described therein has been declined, suspended, or otherwise terminated in
accordance with the terms of this Agreement, CF&Co, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its customary trading and sales practices and applicable state and federal laws,
rules and regulations and the rules of the NASDAQ Capital Market (the “Exchange”), to sell such Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. CF&Co will
provide written confirmation to the Company (including by email correspondence) no later than the opening of the Trading Day (as defined below) next following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the
number of Placement Shares sold on such day, the compensation payable by the Company to CF&Co pursuant to Section 2 with respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of
deductions made by CF&Co (as set forth in Section 5(a)) from gross proceeds for the Placement Shares that it receives from such sales. CF&Co may sell Placement Shares by any method permitted by law deemed to be an “at the
market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on the Exchange, on any other existing trading market for the Common Stock or to or through a market maker. With the prior express
written consent of the Company, which may be provided in its Placement Notice, CF&Co may also sell Placement Shares in privately negotiated transactions. During the term of this Agreement and notwithstanding anything to the contrary herein,
CF&Co agrees that in no event will it or any CF&Co Affiliate engage in any market making, bidding, stabilization or other trading activity with regard to the Common Stock if such activity would be prohibited under Regulation M or other
anti-manipulation rules under the Securities Act. For the purposes hereof, “Trading Day” means any day on which shares of the Common Stock are purchased and sold on the principal market on which the Common Stock is listed or
quoted. 
 4. Suspension of Sales. The Company or CF&Co may, upon notice to the other party in writing
(including by email correspondence to each of the individuals of the other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via
auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission or email correspondence to each of the individuals of the other party set forth on Schedule 2), suspend any sale of Placement Shares; provided,
however, that such suspension shall not affect or impair either party’s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the Parties agrees that no such notice under this
Section 4 shall be effective against the other unless it is made to one of the individuals named on Schedule 2 hereto, as such schedule may be amended from time to time. 

5. Representations and Warranties of the Company. The Company represents and warrants to, and agrees with, CF&Co that as
of each Applicable Time (as defined in Section 19(a)): 

  
 3 

 (a) Compliance with Registration Requirements. The Registration
Statements have been filed with the Commission under the Securities Act and declared effective by the Commission under the Securities Act. The Company has complied with all requests of the Commission for additional or supplemental information. No
stop order suspending the effectiveness of the Registration Statements are in effect and no proceedings for such purpose have been instituted or are pending or, to the Company’s knowledge, are contemplated or threatened by the Commission. The
Company satisfied all applicable requirements for the use of Form S-3 under the Securities Act when the Registration Statements were filed. The Commission has not issued an order preventing or suspending the use of the base prospectus, any Free
Writing Prospectus (as defined below) or the Prospectus relating to the proposed offering of the Placement Shares and no proceedings for such purpose have been instituted or are pending or, to the Company’s knowledge, are contemplated or
threatened by the Commission. The Prospectus delivered to CF&Co for use in connection with the offering of Placement Shares was, at the time of such delivery, identical to the electronically transmitted copies thereof filed with the Commission
pursuant to IDEA, except to the extent permitted by Regulation S-T. At the respective times each part of the Registration Statements and each amendment thereto became effective or was deemed effective, as the case may be, the Registration Statements
complied and will comply in all material respects with the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. The immediately preceding sentence does not apply to statements in or omissions from the Registration Statements or any amendments or supplements thereto based upon and in conformity with written information furnished to the
Company by CF&Co specifically for use therein. 
 (b) Delivery of Offering Materials. The Company
has delivered to CF&Co, or made available through IDEA, one complete copy of each Registration Statement and of each consent of experts filed as a part thereof, and conformed copies of each Registration Statement (without exhibits), and the
Prospectus, as amended or supplemented, in such quantities and at such places as CF&Co has reasonably requested. 
 (c) Prospectus. Neither the Prospectus nor any amendments or supplements thereto, at the time the Prospectus or any such amendment or supplement was issued, as of the date hereof and at each
Applicable Time, as the case may be, included or will include an untrue statement of a material fact or omitted or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The foregoing sentence does not apply to statements in or omissions from the Prospectus or any amendments or supplements thereto based upon and in conformity with written information furnished to the Company by
CF&Co specifically for use therein. 
 (d) Financial Information. The financial statements of the
Company, together with the related schedules and notes thereto, set forth or included or incorporated by reference in the Registration Statements and the Prospectus fairly present, in all material respects, the financial condition of the Company as
of and at the dates indicated and the results of operations, changes in financial position, stockholders’ equity and cash flows for the periods therein specified. Such financial statements, schedules, and notes are in conformity with generally
accepted accounting principles as consistently applied in the United States throughout the 

  
 4 

 
periods involved (except as otherwise stated therein). Any selected financial data included or incorporated by reference in the Registration Statements and the Prospectus present fairly the
information shown therein and, to the extent based upon or derived from the financial statements, have been compiled on a basis consistent with the financial statements presented therein. Any pro forma financial statements of the Company, and the
related notes thereto, included or incorporated by reference in the Registration Statements and the Prospectus present fairly the information shown therein, have been prepared in accordance with the Commission’s rules and guidelines with
respect to pro forma financial statements and have been properly compiled on the basis described therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the
transactions and circumstances referred to therein. The Company does not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), not disclosed in the Registration Statements and the
Prospectus. No other financial statements are required to be set forth or to be incorporated by reference in the Registration Statements or the Prospectus under the Securities Act. 

(e) Incorporated Documents. Each document incorporated or deemed to be incorporated by reference in the
Registration Statements or the Prospectus heretofore filed, at the time it was or hereafter is filed with the Commission, conformed and will conform when filed in all material respects with the requirements of the Exchange Act and the rules and
regulations promulgated thereunder; no such document when it was filed (or, if an amendment with respect to any such document was filed, when such amendment was filed), contained an untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein not misleading; and no such document, when it is filed, will contain an untrue statement of a material fact or will omit to state a material fact required to be
stated therein or necessary in order to make the statements therein not misleading. 
 (f) Distribution
of Materials; Free Writing Prospectuses. The Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities Act. The Company has not, directly or indirectly, distributed
and will not distribute any prospectus or other offering material in connection with the offering and sale of the Placement Shares other than the Prospectus and other materials, if any, permitted under the Securities Act to be distributed. Each
Issuer Free Writing Prospectus (as defined below in Section 19(b)) relating to the Placement Shares that (i) was required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule
433(d)(5)(i), in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g), as of its issue date and as of each Applicable Time
(as defined below in Section 19(a)), did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statements or the Prospectus, including any
incorporated document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written
information furnished to the Company by CF&Co specifically for use therein. The Company has satisfied or will satisfy the conditions in Rule 433 so as not to be required to file with the Commission any electronic road show. 

  
 5 

 (g) Organization. The Company has been duly incorporated and is
validly existing as a corporation in good standing under the laws of the state of Delaware with the corporate power and authority necessary to own, hold, lease and/or operate its assets and properties and to conduct the business in which it is
engaged as described in the Registration Statements and Prospectus; and the Company is duly qualified as a foreign entity to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of
the ownership or leasing of property or the conduct of business, except where the failure, individually or in the aggregate, to be so qualified and be in good standing would not have a material adverse effect on (i) the consolidated business,
operations, assets, properties, financial condition, reputation, prospects, or results of operations of the Company and any subsidiaries which may be incorporated or formed from time to time (the “Subsidiaries”) taken as a
whole, (ii) the transactions contemplated hereby, or (iii) the ability of the Company to perform its obligation under this Agreement (collectively, a “Material Adverse Effect”). The Company has full corporate power
and authority necessary to enter into and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. Except as disclosed in the Registration Statements and the Prospectus, the Company is in compliance with
the laws, orders, rules, regulations and directives applicable to it, except for any noncompliance that, individually, or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

(h) Subsidiaries. The Company has no “significant subsidiaries” (as such term is defined in Rule
1-02 of Regulation S-X promulgated under the Securities Act). Except as disclosed in the Registration Statements and the Prospectus, the Company does not own, directly or indirectly, any shares of stock or any other equity interests or long-term
debt securities of any corporation, firm, partnership, joint venture, association or other entity. 

(i) No Violation or Default. Except as disclosed in the Registration Statements and the Prospectus, neither
the Company nor any of its Subsidiaries is (i) in violation of any provision of its charter or bylaws or similar organizational documents, (ii) in default in any respect, and no event has occurred which, with notice or lapse of time or
both, would constitute such a default, in the due performance or observance of any term, covenant, or condition of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition,
covenant or instrument to which it is a party or by which it is bound or to which any of its property or assets is subject, (iii) in violation in any respect of any statute, law, rule, regulation, ordinance, judgment, order or decree of any
court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company, its Subsidiaries or any of its properties, as applicable (including, without limitation, those administered by the
Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by
the FDA), or (iv) in violation of any rule or regulation of any self-regulating organization or other non-governmental regulatory authority (including, without limitation, the rules and regulations of the Exchange) except, with respect to
clauses (ii), (iii), and (iv), any violations or defaults which, singularly or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. The execution, delivery and performance of this Agreement, the
issuance and sale of the Placement Shares and the consummation of the transactions contemplated hereby will not conflict with, or result in any breach of or constitute a default 

  
 6 

 
under (nor constitute any event which with notice, lapse of time or both would result in any breach of, or constitute a default under), (i) any provision of the charter, bylaws or
organizational documents, as the case may be, of the Company or any of its Subsidiaries, (ii) any provision of any contract, license, repurchase agreement, management agreement, indenture, mortgage, deed of trust, bank loan or credit agreement,
note, lease or other evidence of indebtedness, or any lease, contract or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries, or any of their respective assets
or properties may be bound or affected, except for any breach or default that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect, (iii) any federal, state, local or foreign law, regulation or
rule or any decree, judgment or order applicable to the Company or any of its Subsidiaries, or (iv) any rule or regulation of any self-regulating organization or other non-governmental regulatory authority (including, without limitation, the
rules and regulations of the Exchange), except for any breach or default that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

(j) Capitalization. As of December 31, 2010, the Company had an authorized, issued and outstanding
capitalization as set forth on its balance sheet included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010. All of the issued and outstanding shares of capital stock of the Company have been duly and validly
authorized and issued and are fully paid and non-assessable, have been issued in compliance with all federal and state securities laws and were not issued in violation of any preemptive right, resale right, right of first refusal or similar right.

 (k) Authorization; Enforceability. This Agreement has been duly authorized, executed and delivered
by the Company and is a legal, valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors’ rights generally and by general equitable principles and (ii) the indemnification and contribution provisions of Section 9 hereof may be limited by federal or state securities laws and public policy
considerations in respect thereof. 
 (l) Capital Stock and Placement Shares in Proper Form. The
capital stock of the Company, including the Placement Shares, conforms in all material respects to the description thereof contained in the Registration Statements and the Prospectus. The holders of the Placement Shares will not be subject to
personal liability under the Delaware General Corporation Law by reason of being such holders. 

(m) Authorization of Placement Shares. The Placement Shares, or class of shares which the Placement Shares are
part of, when issued and delivered pursuant to the terms approved by the Board of Directors or a duly designated committee thereof, against payment therefor as provided herein, will be duly and validly authorized and issued and fully paid and
non-assessable, free and clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights, and will be registered
pursuant to Section 12 of the Exchange Act. 

  
 7 

 (n) Consents and Permits. (1) Except as disclosed in the
Registration Statements and the Prospectus, the Company and its Subsidiaries have made all filings, applications and submissions required by, and possesses all approvals, licenses, certificates, certifications, clearances, consents, exemptions,
marks, notifications, orders, permits and other authorizations issued by, the appropriate federal, state or foreign regulatory authorities (including, without limitation, the FDA, and any other foreign, federal, state or local government or
regulatory authorities performing functions similar to those performed by the FDA) necessary for the ownership or lease of their respective properties or to conduct its businesses as described in the Registration Statements and the Prospectus
(collectively, “Permits”), except for such Permits the failure of which to possess, obtain or make the same would not reasonably be expected to have a Material Adverse Effect; and neither the Company nor any of its
Subsidiaries has received any written notice of proceedings relating to the limitation, revocation, cancellation, suspension, modification or non-renewal of any such Permit which, singly or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would have a Material Adverse Effect, and has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. (2) No approval, authorization, consent or
order of or filing with any national, state or local governmental or regulatory commission, board, body, authority or agency is required in connection with the issuance and sale of the Placement Shares or the consummation by the Company of the
transactions contemplated hereby (including, without limitation, the Exchange, or approval of the stockholders of the Company (including as may be required pursuant to Rule 5635 of the NASDAQ Marketplace Rules)), other than (i) registration of
the Placement Shares under the Securities Act, (ii) any necessary qualification under the securities or blue sky laws of the various jurisdictions in which the Placement Shares are being offered by CF&Co, (iii) filing of any reports
under the Exchange Act, or (iv) such approvals as may be required by the Conduct Rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”).  

(o) No Preferential Rights. Except as set forth in the Registration Statements and the Prospectus, (i) no
person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act (each, a “Person”), has the right, contractual or otherwise, to cause the Company to issue or sell to such Person any shares
of Common Stock or shares of any other capital stock or other securities of the Company, (ii) no Person has any preemptive rights, resale rights, rights of first refusal, or any other rights (whether pursuant to a “poison pill”
provision or otherwise) to purchase any shares of Common Stock or shares of any other capital stock or other securities of the Company, (iii) except as disclosed to CF&Co or its agents in connection with the transactions contemplated
hereby, no Person has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Placement Shares, and (iv) no Person has the right, contractual or otherwise, to require the Company
to register under the Securities Act any shares of Common Stock or shares of any other capital stock or other securities of the Company, or to include any such shares or other securities in the Registration Statements or the offering contemplated
thereby, whether as a result of the filing or effectiveness of the Registration Statements or the sale of the Placement Shares as contemplated thereby or otherwise. 

(p) Independent Public Accountant. Ernst & Young, LLP, whose report on the financial statements of
the Company is filed with the Commission as part of the Registration 

  
 8 

 
Statements and the Prospectus, are and, during the periods covered by their report, were (i) an independent public accounting firm within the meaning of the Securities Act, (ii) a
registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act), and (iii) not in violation of the auditor independence requirements of the Sarbanes-Oxley Act. 

(q) Enforceability of Agreements. Except as disclosed in the Registration Statements and the Prospectus, all
agreements between the Company and third parties expressly referenced in the Prospectus are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent that (i) enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited be
federal or state securities laws or public policy considerations in respect thereof and except for any other potentially unenforceable term that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

 (r) No Litigation. Except as disclosed in the Registration Statements and the Prospectus, there
are no actions, suits, claims, investigations, inquiries or proceedings pending or, to the Company’s knowledge, threatened, to which either the Company or, to the Company’s knowledge, its Subsidiaries, nor any of their respective officers
or directors, is a party or of which any of their respective properties or other assets is subject at law or in equity, or before or by any federal, state, local or foreign governmental or regulatory commission, board, body, authority or agency, or
before any self-regulating organization or other non-governmental regulatory authority (including, without limitation, the Exchange), which if resolved adversely to the Company or any Subsidiary would, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. 
 (s) Regulatory Filings. Except as disclosed in
the Registration Statements and the Prospectus, neither the Company nor any of its Subsidiaries has failed to file with the applicable regulatory authorities (including, without limitation, the FDA or any foreign, federal, state or local
governmental or regulatory authority performing functions similar to those performed by the FDA) any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect; except as disclosed in the Registration Statements and the Prospectus, all such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable
laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the
aggregate, would not reasonably be expected to have a Material Adverse Effect.
 (t) Certain Market
Activities. Neither the Company nor, to the Company’s knowledge, any of its Subsidiaries, nor, to the Company’s knowledge, any of their respective directors, officers or controlling persons has taken, directly or indirectly, any action
designed, or that has constituted or might reasonably be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the
Placement Shares. 

  
 9 

 (u) Broker/Dealer Relationships. Neither the Company nor any of
its Subsidiaries or any related entities (i) is required to register as a “broker” or “dealer” in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries,
controls or is a “person associated with a FINRA member” or “associated person of a FINRA member” (within the meaning of Article I of the Bylaws of the NASD). 

(v) No Reliance. The Company has not relied upon CF&Co or legal counsel for CF&Co for any legal, tax
or accounting advice in connection with the offering and sale of the Placement Shares. 
 (w) Taxes.
Except as disclosed in the Registration Statements and the Prospectus, the Company and, to the Company’s knowledge, any of its Subsidiaries has filed on a timely basis (taking into account all applicable extensions) all necessary federal,
state, local and foreign income and franchise tax returns, if any such returns were required to be filed, through the date hereof and have paid all taxes shown as due thereon except for any failure to file or pay which, individually or in the
aggregate, would not reasonably be expected to have a Material Adverse Effect. No tax deficiency has been asserted against the Company or, to the Company’s knowledge, any of its Subsidiaries, nor does the Company know of any tax deficiency that
is likely to be asserted against any such entity that, if determined adversely to any such entity, could reasonably be expected to have a Material Adverse Effect. All tax liabilities, if any, are adequately provided for on the books of the Company
and, to the Company’s knowledge, any of its Subsidiaries, except for such tax liabilities that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

(x) Intellectual Property. Except as disclosed in the Registration Statements and the Prospectus, the Company
and its Subsidiaries own, possess, license or have other rights to use all foreign and domestic patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade
secrets, technology, Internet domain names, know-how and other intellectual property (collectively, the “Intellectual Property”), necessary for the conduct of their respective businesses as now conducted except to the extent
that the failure to own, possess, license or otherwise hold adequate rights to use such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in the Registration Statements and
the Prospectus, (a) there are no rights of third parties to any such Intellectual Property owned by the Company and its Subsidiaries; (b) to the Company’s knowledge, there is no infringement by third parties of any such Intellectual
Property; (c) to the Company’s knowledge, there is no pending or threatened action, suit, proceeding or claim by others challenging the Company’s and its Subsidiaries’ rights in or to any such Intellectual Property, and the
Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (d) to the Company’s knowledge, there is no pending or threatened action, suit, proceeding or claim by others challenging
the validity or scope of any such Intellectual Property; (e) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company and its Subsidiaries infringe or otherwise violate any
patent, trademark, copyright, trade secret or other proprietary rights of others; (f) to the Company’s knowledge, there is no third-party U.S. patent or published U.S. patent application which contains claims for which an Interference
Proceeding (as defined in 35 U.S.C. § 135) has been commenced against any patent or patent application described in the 

  
 10 

 
Prospectus as being owned by or licensed to the Company; and (g) the Company and its Subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has
been licensed to the Company or such Subsidiary, and all such agreements are in full force and effect, except, in the case of any of clauses (a)-(g) above, for any such infringement by third parties or any such pending or threatened suit,
action, proceeding or claim as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 
 (y) Clinical Studies. The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company and its Subsidiaries were and, if still pending, are
being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or
regulatory authority performing functions similar to those performed by the FDA). Except as set forth in the Registration Statements and Prospectus, neither the Company nor any of its Subsidiaries has received any notices or other
correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring
the termination or suspension of such studies or tests. 
 (z) Compliance Program. Except as
disclosed in the Registration Statements and the Prospectus, the Company has established and administers a compliance program applicable to the Company, to assist the Company and the directors, officers and employees of the Company in complying with
applicable regulatory guidelines (including, without limitation, those administered by the FDA and any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA); except
where such noncompliance would not reasonably be expected to have a Material Adverse Effect. 

(aa) Environmental Laws. Except as disclosed in the Registration Statements and the Prospectus, the Company
and its Subsidiaries: (i) are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or
toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (ii) have received and are in compliance with all permits, licenses and other approvals required of them under applicable
Environmental Laws to conduct their respective businesses as described in the Registration Statements and the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation of any
disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, or
other approvals or any such liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (bb) Accounting Controls. Except as disclosed in the Registration Statements and the Prospectus, the Company and its Subsidiaries maintain a system of internal accounting controls as
defined in Rule 13a-15f and 15d-15f of the Exchange Act. 

  
 11 

 (cc) Disclosure Controls. Except as disclosed in the
Registration Statements and the Prospectus, the Company has established and maintains disclosure controls and procedures as defined in Rule 13a-15e and 15d-15e of the Exchange Act. 

(dd) Sarbanes-Oxley Act. Except as disclosed in the Registration Statements and the Prospectus, the
Company, its Subsidiaries and the Company’s directors and officers are each in compliance in all material respects with all applicable effective provisions of the Sarbanes-Oxley Act and the rules and regulations of the Commission and the
Exchange promulgated thereunder. 
 (ee) Finder’s Fees. Neither the Company nor any of its
Subsidiaries has incurred any liability for any finder’s fees or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to CF&Co pursuant to this Agreement. 

(ff) Labor Disputes. Except as disclosed in the Registration Statements and the Prospectus, the Company nor
any of its Subsidiaries is engaged in any unfair labor practice; except for matters which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) there is no (A) unfair labor practice
complaint pending or, to the Company’s knowledge, threatened against the Company or its Subsidiaries before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under collective bargaining agreements
is pending or, to the Company’s knowledge, threatened, (B) strike, labor dispute, slowdown or stoppage pending or, to the Company’s knowledge, threatened against the Company or any of its Subsidiaries and (C) union representation
dispute currently existing concerning the employees of the Company or any of its Subsidiaries, and (ii) to the Company’s knowledge, (A) no union organizing activities are currently taking place concerning the employees of the Company
or any of its Subsidiaries, and (B) there has been no violation of any federal, state, local, or foreign law relating to discrimination in the hiring, promotion or pay of employees or any applicable wage or hour laws concerning the employees of
the Company. 
 (gg) Investment Company Act. Except as disclosed in the Registration Statements and
the Prospectus, neither the Company nor any of its Subsidiaries, after giving effect to the offering and sale of the Placement Shares, will be (i) required to register as an “investment company” or an entity “controlled” by
an “investment company,” as such terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”), or (ii) a “business development company” (as defined in
Section 2(a)(48) of the Investment Company Act). 
 (hh) Casualty. Except as disclosed in the
Registration Statements and the Prospectus, neither the Company nor, to the Company’s knowledge, any of its Subsidiaries has sustained any loss or interference with its respective business from fire, explosion, flood or other calamity, whether
or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, in each case that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 

  
 12 

 (ii) Underwriter Agreements. Except as disclosed in the
Registration Statements and the Prospectus, the Company is not a party to any agreement with an agent or underwriter for any other “at-the-market” or continuous equity transaction. 

(jj) ERISA. Except as disclosed in the Registration Statements and the Prospectus, the Company and its
Subsidiaries are in compliance with all presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”), except
for any noncompliance that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Except as disclosed in the Registration Statements and the Prospectus, no “reportable event” (as defined in
section 4043 of ERISA) for which the Pension Benefit Guaranty Corporation has not waived the notice requirement has occurred in the past three years with respect to any “pension plan” (as defined in ERISA) for which the Company and its
Subsidiaries would reasonably expect to have any liability. Except as disclosed in the Registration Statements and the Prospectus, the Company and its Subsidiaries have not incurred and do not reasonably expect to incur liability under
(i) Title IV of ERISA with respect to termination of, or withdrawal from, any “pension plan” or (ii) Sections 412 or 4971 of the Code. Except as disclosed in the Registration Statements and the Prospectus, each “pension
plan” for which the Company or its Subsidiaries would have any liability that is intended to be qualified under Section 401(a) of the Code has received a favorable determination or opinion letter to that effect and, to the Company’s
knowledge, no event has occurred since the date of such letter that could reasonably be expected to result in the loss of such qualification. 
 (kk) CF&Co Purchases. The Company acknowledges and agrees that CF&Co has informed the Company that CF&Co may, to the extent permitted under the Securities Act and the Exchange Act,
purchase and sell shares of Common Stock for its own account while this Agreement is in effect, provided, that (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent CF&Co may
engage in sales of Placement Shares purchased or deemed purchased from the Company as a “riskless principal” or in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or
sales by CF&Co. 
 (ll) No Improper Practices. Except as disclosed in the Registration Statements
and the Prospectus, (i) neither the Company nor, to the Company’s knowledge, its Subsidiaries, nor to the Company’s knowledge, any of their respective executive officers has, in the past five years, made any unlawful contributions to
any candidate for any political office (or failed fully to disclose any contribution in violation of law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other
person charged with similar public or quasi-public duty in violation of any law or of the character required to be disclosed in the Prospectus; (ii) no relationship, direct or indirect, exists between or among the Company or, to the
Company’s knowledge, any Subsidiary or any affiliate of any of them, on the one hand, and the directors, officers and stockholders of the Company or, to the Company’s knowledge, any Subsidiary, on the other hand, that is required by the
Securities Act to be described in the Registration Statements and the Prospectus that is not so described; (iii) no relationship, direct or indirect, exists between or among the Company or any Subsidiary or any affiliate of them, on the one
hand, and the directors, officers, 

  
 13 

 
stockholders or directors of the Company or, to the Company’s knowledge, any Subsidiary, on the other hand, that is required by the rules of the FINRA to be described in the Registration
Statements and the Prospectus that is not so described; (iv) except as described in the Prospectus, there are no material outstanding loans or advances or material guarantees of indebtedness by the Company or, to the Company’s knowledge,
any Subsidiary to or for the benefit of any of their respective officers or directors or any of the members of the families of any of them; (v) the Company has not offered, or caused any placement agent to offer, Common Stock to any person with
the intent to influence unlawfully (A) a customer or supplier of the Company or any Subsidiary to alter the customer’s or supplier’s level or type of business with the Company or any Subsidiary or (B) a trade journalist or
publication to write or publish favorable information about the Company or any Subsidiary or any of their respective products or services, and, (vi) neither the Company nor any Subsidiary nor, to the Company’s knowledge, any employee or
agent of the Company or any Subsidiary has made any payment of funds of the Company or any Subsidiary or received or retained any funds in violation of any law, rule or regulation (including, without limitation, the Foreign Corrupt Practices Act of
1977), which payment, receipt or retention of funds is of a character required to be disclosed in the Registration Statements or the Prospectus. 
 (mm) Title to Property. Except as disclosed in the Registration Statements and the Prospectus, the Company and its Subsidiaries have good and marketable title to all property (real and
personal) described in the Registration Statements and the Prospectus as being owned by any of them, free and clear of all material liens, claims, security interests or other encumbrances, except to the extent such material liens, claims, security
interests or other encumbrances are disclosed in the Registration Statements and the Prospectus; all the property described in the Registration Statements and the Prospectus as being held under lease by the Company or any Subsidiary is held thereby
under valid, subsisting and enforceable leases. 
 (nn) Insurance. Except as disclosed in the
Registration Statements and the Prospectus, the Company and its Subsidiaries maintain insurance covering their respective properties, operations, personnel and businesses as the Company reasonably deems adequate; such insurance insures against such
losses and risks to an extent which the Company reasonably believes is adequate and in accordance with customary industry practice to protect the Company and its Subsidiaries and their respective businesses; all such insurance is fully in force on
the date hereof and will be fully in force at the time of purchase; neither the Company nor its Subsidiaries has reason to believe that it will not be able to renew any such insurance as and when such insurance expires. 

(oo) Data Reliable and Accurate. All statistical or market-related data included or incorporated by reference
in the Registration Statements and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources to the extent
required. 
 (pp) NASDAQ: Registration. The Common Stock is registered pursuant to Section 12(b)
of the Exchange Act and is listed on the Exchange, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Exchange, nor except as disclosed in the
Registration Statements and the Prospectus, has the Company received any notification that the 

  
 14 

 
Commission or FINRA is contemplating terminating such registration or listing. Except as disclosed in the Registration Statements and the Prospectus, the Company has complied in all material
respects with the applicable requirements of the Exchange for maintenance of inclusion of the Common Stock thereon. The Company has filed a Notification of Listing of Additional Shares with the Exchange with respect to the Placement Shares.

 (qq) The operations of the Company and its Subsidiaries are and have been conducted at all times in
material compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and
regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, “Money Laundering Laws”) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 Any certificate signed by an officer of the Company and delivered to CF&Co or to counsel for CF&Co pursuant to or in
connection with this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to CF&Co as to the matters set forth therein. 
 6. Sale and Delivery; Settlement. 
 (a) Sale of
Placement Shares. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, upon CF&Co’s acceptance of the terms of a Placement Notice, and unless the sale of
the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, CF&Co, for the period specified in the Placement Notice, will use its commercially reasonable efforts
consistent with its normal trading and sales practices and applicable laws to sell such Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. The Company acknowledges and agrees that
(i) there can be no assurance that CF&Co will be successful in selling Placement Shares, (ii) CF&Co will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any
reason other than a failure by CF&Co to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Placement Shares as required under this Agreement and
(iii) CF&Co shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by CF&Co and the Company. 

(b) Settlement of Placement Shares. Unless otherwise specified in the applicable Placement
Notice, settlement for sales of Placement Shares will occur on the third (3rd) Business Day (or such earlier day as is industry practice for regular-way trading) following the date on which such sales are made (each, a “Settlement Date” and the
first such settlement date, the “First Delivery Date”). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will
be equal to the aggregate sales price received by CF&Co at which such Placement Shares were sold, after deduction for (i) CF&Co’s commission, discount or other compensation for such

  
 15 

 
sales payable by the Company pursuant to Section 2 hereof, and (ii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.

 (c) Delivery of Placement Shares. On or before each Settlement Date, the Company will, or will
cause its transfer agent to, electronically transfer the Placement Shares being sold by crediting CF&Co’s or its designee’s account (provided CF&Co shall have given the Company written notice of such designee at least one Business
Day prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties hereto which in all cases shall be freely
tradable, transferable, registered shares in good deliverable form. On each Settlement Date, CF&Co will deliver the related Net Proceeds in same-day funds to an account designated by the Company on, or prior to, the Settlement Date. The Company
agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date, the Company will, in addition to and in no way limiting the rights and obligations set forth in
Section 9 (Indemnification and Contribution), (i) hold CF&Co harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by
the Company and (ii) pay to CF&Co any commission, discount, or other compensation to which it would otherwise have been entitled absent such default; provided, however, that the Company shall not be obligated to so indemnify
and reimburse CF&Co if the Placement Shares are not timely delivered due to (i) a suspension or material limitation in trading in securities generally on the Exchange; (ii) a general moratorium on commercial banking activities declared
by either federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iii) an outbreak or escalation of hostilities or acts of terrorism involving
the United States or a declaration by the United States of a national emergency or war; or (iv) any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere. 

(d) Denominations; Registration. Certificates for the Placement Shares, if any, shall be in such
denominations and registered in such names as CF&Co may request in writing at least one full business day before the Settlement Date. The certificates for the Placement Shares, if any, will be made available for examination and packaging by
CF&Co in The City of New York not later than noon (New York time) on the business day prior to the Settlement Date. 
 (e) Limitations on Offering Size. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after giving effect to the sale of such
Placement Shares, the aggregate gross sales proceeds sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount, (B) the amount available for offer
and sale under the currently effective Registration Statements and (C) the amount authorized from time to time to be issued and sold under this Agreement by the Company’s board of directors, a duly authorized committee thereof or a duly
authorized executive committee, and notified to CF&Co in writing; provided, however, that in no event shall the Company issue or sell through CF&Co such number of Shares that would cause the Company to not satisfy the eligibility
requirements for use of Form S-3. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares at a price lower than the minimum price authorized from time to time by the

  
 16 

 
Company’s board of directors, duly authorized committee thereof or a duly authorized executive committee, and notified to CF&Co in writing. Further, under no circumstances shall the
aggregate offering amount of Placement Shares sold pursuant to this Agreement, including any separate underwriting or similar agreement covering principal transactions described in Section 1 of this Agreement, exceed the Maximum Amount.

 (f) The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of
Placement Shares shall only be effected by or through CF&Co on any single given day; provided, however, that (1) the foregoing limitation shall not apply to (i) the exercise of any option, warrant, right or any conversion
privilege set forth in the instrument governing such security or (ii) sales solely to employees or security holders of the Company or its Subsidiaries, or to a trustee or other person acquiring such securities for the accounts of such persons,
and (2) such limitation shall not apply on any day during which no sales are made pursuant to this Agreement. 

7. Covenants of the Company. The Company covenants and agrees with CF&Co that: 

(a) Registration Statement Amendments; Payment of Fees. After the date of this Agreement and during any period
in which a Prospectus relating to any Placement Shares is required to be delivered by CF&Co under the Securities Act with respect to a pending sale of the Placement Shares (including in circumstances where such requirement may be satisfied
pursuant to Rule 172 under the Securities Act), the Company will notify CF&Co promptly of the time when any subsequent amendment to the Registration Statements, other than documents incorporated by reference, has been filed with the
Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed and any request by the Commission for any amendment or supplement to the Registration Statements or Prospectus or for additional information.

 (b) Notice of Commission Stop Orders. During any period in which a Prospectus relating to any
Placement Shares is required to be delivered by CF&Co under the Securities Act with respect to a pending sale of Placement Shares, the Company will advise CF&Co, promptly after it receives notice or obtains knowledge thereof, of the issuance
or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statements or any other order preventing or suspending the use of the Prospectus, of the suspension of the qualification of the Placement
Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding for any such purpose or any examination pursuant to Section 8(e) of the Securities Act, or if the Company becomes the subject of a proceeding
under Section 8A of the Securities Act in connection with the offering of the Placement Shares; and the Company will promptly use its commercially reasonable efforts to prevent the issuance of any stop or other order or to obtain its withdrawal
if such a stop or other order should be issued. 
 (c) Delivery of Prospectus; Subsequent Changes.
During any period in which a Prospectus relating to the Placement Shares is required to be delivered by CF&Co under the Securities Act with respect to a pending sale of the Placement Shares (including in circumstances where such requirement may
be satisfied pursuant to Rule 172 under the Securities Act), the Company will comply with all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates

  
 17 

 
all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or
under the Exchange Act. If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statements or Prospectus to comply with the Securities Act, the Company will promptly notify
CF&Co to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statements or Prospectus (at the expense of the Company) so as to correct such statement or omission or
effect such compliance. 
 (d) Listing of Placement Shares. During any period in which the Prospectus
relating to the Placement Shares is required to be delivered by CF&Co under the Securities Act with respect to a pending sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under
the Securities Act), the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on the Exchange. 
 (e) Delivery of Registration Statements and Prospectus. The Company will furnish to CF&Co and its counsel (at the expense of the Company) copies of the Registration Statements, the
Prospectus (including all documents incorporated by reference therein) and all amendments and supplements to the Registration Statements or Prospectus that are filed with the Commission during any period in which a Prospectus relating to the
Placement Shares is required to be delivered under the Securities Act. The copies of the Registration Statements and the Prospectus and any supplements or amendments thereto furnished to CF&Co will be identical to the electronically transmitted
copies thereof filed with the Commission pursuant to IDEA, except to the extent permitted by Regulation S-T. Notwithstanding the foregoing, the Company will not be required to furnish any document (other than the Prospectus) to CF&Co to the
extent such document is available on IDEA. 
 (f) Earnings Statement. The Company will make generally
available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of
Section 11(a) and Rule 158 of the Securities Act. “Earnings statement” and “make generally available” will have the meanings contained in Rule 158 under the Securities Act. 

(g) Expenses. The Company, whether or not the transactions contemplated hereunder are consummated or this
Agreement is terminated, in accordance with the provisions of Section 11 hereunder, will pay all expenses incident to the performance of the Company’s obligations hereunder, which the parties acknowledge include expenses relating to:
(i) the preparation, printing and filing of the Registration Statements and each amendment and supplement thereto, of each Prospectus and of each amendment and supplement thereto, and of this Agreement, (ii) the preparation, issuance and
delivery of the Placement Shares, (iii) the printing and delivery to CF&Co of copies of the Prospectus and any amendments and supplements thereto, (iv) the fees and expenses incurred in connection with the listing or qualification of
the Placement Shares for trading on the Exchange, and (v) the filing fees and expenses, if any, of the Commission and FINRA. 

  
 18 

 (h) Use of Proceeds. The Company will use the Net Proceeds as
described in the Prospectus in the section entitled “Use of Proceeds.” 
 (i) Notice of Other
Sales. During either the pendency of any Placement Notice given hereunder, or any period in which the Prospectus relating to the Placement Shares is required to be delivered by CF&Co, the Company shall provide CF&Co notice as promptly as
reasonably possible before it offers to sell, contracts to sell, sells, grants any option to sell or otherwise disposes of any shares of Common Stock (other than Placement Shares offered pursuant to the provisions of this Agreement) or securities
convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire Common Stock; provided, that such notice shall not be required in connection with the (i) issuance, grant or sale of Common Stock, options
to purchase shares of Common Stock or Common Stock issuable upon the exercise of options or other equity awards pursuant to any employee or director stock option or benefits plan or stock ownership plan or issuances permitted by FINRA, (ii) the
issuance or sale of Common Stock pursuant to any dividend reinvestment plan that the Company may adopt from time to time or (iii) the issuance of Common Stock upon the exercise of any currently outstanding warrants, options or other rights in
effect or outstanding and disclosed in filings by the Company available on EDGAR. 
 (j) Change of
Circumstances. The Company will, at any time during the pendency of a Placement Notice, advise CF&Co promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any
material respect any opinion, certificate, letter or other document required to be provided to CF&Co pursuant to this Agreement. 
 (k) Due Diligence Cooperation. The Company will cooperate with any reasonable due diligence review conducted by CF&Co or its agents in connection with the transactions contemplated hereby,
including, without limitation, providing information and making available documents and senior corporate officers, during regular business hours and at the Company’s principal offices, as CF&Co may reasonably request. 

(l) Required Filings Relating to Placement of Placement Shares. The Company agrees that on such dates as the
Securities Act shall require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act (each and every filing date under Rule 424(b), a “Filing
Date”), which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold through CF&Co, the Net Proceeds to the Company and the compensation payable by the Company to CF&Co with respect
to such Placement Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market.

 (m) Representation Dates; Certificate. Three Trading Days prior to the First Delivery Date and
each time the Company: 
  

	 	(i)	 files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering of
securities other than the Placement Shares) the Registration 

  
 19 

	 	
Statements or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the
Registration Statements or the Prospectus relating to the Placement Shares; 

  

	 	(ii)	files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material amendment to the previously
filed Form 10-K); 

  

	 	(iii)	files its quarterly reports on Form 10-Q under the Exchange Act; or 

  

	 	(iv)	files a current report on Form 8-K containing amended financial information (other than information “furnished” pursuant to Items 2.02 or 7.01 of
Form 8-K) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date”), 

the Company shall furnish CF&Co with a certificate, in the form attached hereto as Exhibit 7(m) within three (3) Trading
Days of any Representation Date. The requirement to provide a certificate under this Section 7(m) shall be waived for any Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until
the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date; provided, however, that such
waiver shall not apply for any Representation Date on which the Company files its annual report on Form 10-K. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the
Company relied on such waiver and did not provide CF&Co with a certificate under this Section 7(m), then before the Company delivers the Placement Notice or CF&Co sells any Placement Shares, the Company shall provide CF&Co
with a certificate, in the form attached hereto as Exhibit 7(m), dated the date of the Placement Notice. 

(n) Legal Opinion. On or before the date of the first Placement Notice is given hereunder, the Company shall
cause to be furnished to CF&Co a written opinion dated as of the date of such Placement Notice of Cooley LLP (the “Company Counsel”), in a form reasonably acceptable to CF&Co and its counsel. Within three
(3) Trading Days of each subsequent Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit 7(m) for which no waiver is applicable, the Company shall cause to be
furnished to CF&Co a written opinion of Company Counsel in a form reasonably acceptable to CF&Co and its counsel. 
 (o) Comfort Letter. Three Trading Days prior to the First Delivery Date and within three (3) Trading Days of each Representation Date with respect to which the Company is obligated to
deliver a certificate in the form attached hereto as Exhibit 7(m) for which no waiver is applicable, the Company shall cause its independent accountants (and any other independent accountants whose report is included in the Registration
Statements or the Prospectus), to furnish CF&Co letters (the “Comfort Letters”) in form and substance satisfactory to CF&Co, (i) confirming that they are an independent registered public

  
 20 

 
accounting firm within the meaning of the Securities Act, the Exchange Act, and the PCAOB, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the
financial information and other matters ordinarily covered by accountants’ “comfort letters” to underwriters in connection with registered public offerings (the first such letter, the “Initial Comfort Letter”)
and (iii) updating the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statements and the Prospectus,
as amended and supplemented to the date of such letter. 
 (p) Market Activities. The Company will
not, directly or indirectly (i) take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the
sale or resale of the Placement Shares or (ii) sell, bid for, or purchase the Placement Shares to be issued and sold pursuant to this Agreement, or pay anyone any compensation for soliciting purchases of the Placement Shares to be issued and
sold pursuant to this Agreement other than CF&Co. 
 (q) Filings with the Exchange. The Company
will timely file with the Exchange all material documents and notices required by the Exchange of companies that have or will issue securities that are traded on the Exchange. 

(r) Securities Act and Exchange Act. The Company will use its commercially reasonable efforts to comply with
all requirements imposed upon it by the Securities Act and the Exchange Act as from time to time in force, so far as necessary to permit the continuance of sales of, or dealings in, the Placement Shares as contemplated by the provisions hereof and
the Prospectus. 
 (s) No Offer to Sell. Other than a free writing prospectus (as defined in Rule 405
under the Securities Act) approved in advance in writing by the Company and CF&Co in its capacity as principal or agent hereunder, neither CF&Co nor the Company (including its agents and representatives, other than CF&Co in its capacity
as such) will, directly or indirectly, make, use, prepare, authorize, approve or refer to any free writing prospectus relating to the Placement Shares to be sold by CF&Co as principal or agent hereunder. 

(t) Transfer Agent. The Company shall maintain, at its expense, a registrar and transfer agent for the Common
Stock. 
 (u) Disclosure of Sales. The Company will disclose in its quarterly reports on Form
10-Q and in its annual report on Form 10-K the number of Placement Shares sold through CF&Co during the relevant quarter. 
 (v) Market Stabilization. The Company will not, and will use its commercially reasonable efforts to cause its officers, trustees and affiliates not to, (i) take, directly or indirectly,
any action designed to stabilize or manipulate the price of any security of the Company, or which may cause or result in, or which might in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of
any security of the Company, to facilitate the sale or resale of any of the Placement Shares, (ii) sell, bid for, purchase or pay anyone any compensation for soliciting purchases of the Placement Shares

  
 21 

 
during the pendency of any Placement Notice or (iii) pay or agree to pay to any person any compensation for soliciting any order to purchase any other securities of the Company during the
pendency of any Placement Notice; provided, however, that upon consent of CF&Co the Company may bid for and purchase Common Stock in accordance with Rule 10b-18 under the Exchange Act. 

(w) Available Shares. The Company will ensure that there are at all times sufficient shares of Common Stock to
provide for the issuance, free of any preemptive rights, out its authorized but unissued shares of Common Stock, of the Maximum Amount. 
 8. Conditions to CF&Co’s Obligations. The obligations of CF&Co hereunder with respect to a Placement Notice will be subject to the continuing accuracy and completeness of the
representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by CF&Co of a due diligence review satisfactory to CF&Co in its reasonable judgment, and to the
continuing satisfaction (or waiver by CF&Co in its sole discretion) of the following additional conditions: 

(a) Registration Statements Effective. The Registration Statements shall have become effective and together
shall be available for the sale of all Placement Shares contemplated to be issued by any Placement Notice. 

(b) No Material Notices. None of the following events shall have occurred and be continuing: (i) receipt
by the Company of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statements, the response to which would require any
post-effective amendments or supplements to the Registration Statements or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the
Registration Statements or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; (iv) the occurrence of any event that makes any material statement made in the Registration Statements or the Prospectus untrue in any material
respect or that requires the making of any changes in the Registration Statements, related Prospectus or documents so that, in the case of the Registration Statements, it will not contain any materially untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(c) Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports
filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a
Material Adverse Effect, the effect of which, in the reasonable judgment of CF&Co (without relieving the Company of any obligation or liability it may otherwise have), is so material as 

  
 22 

 
to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus. 

(d) Legal Opinion. CF&Co shall have received the opinion of Company Counsel required to be delivered
pursuant to Section 7(n) on or before the date on which such delivery of such opinion is required pursuant to Section 7(n). 
 (e) Comfort Letter. CF&Co shall have received the Comfort Letter required to be delivered pursuant to Section 7(o) on or before the date on which such delivery of such opinion
is required pursuant to Section 7(o). 
 (f) Representation Certificate. CF&Co shall
have received the certificate required to be delivered pursuant to Section 7(m) on or before the date on which delivery of such certificate is required pursuant to Section 7(m). 

(g) No Exchange Suspension or FINRA Objection. Trading in the Common Stock shall not have been suspended on
the Exchange. FINRA shall not have objected to the fairness or reasonableness of the terms or arrangements under this Agreement. 
 (h) Other Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(m), the Company shall use its commercially reasonable efforts to
furnish to CF&Co such appropriate further information, certificates and documents as CF&Co may reasonably request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof. The Company
will furnish CF&Co with such conformed copies of such opinions, certificates, letters and other documents as CF&Co shall reasonably request. 
 (i) Securities Act Filings Made. All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall
have been made within the applicable time period prescribed for such filing by Rule 424. 
 (j) Approval
for Listing. The Placement Shares shall either have been (i) approved for listing on the Exchange, subject only to notice of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on the
Exchange at, or prior to, the issuance of any Placement Notice. 
 (k) Termination of Agreement.
If any condition specified in this Section 8 shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated by CF&Co by notice to the Company. Notice of such cancellation shall be given in writing
and addressed to each of the individuals of the Company set forth on Schedule 2. 
 (l) No
Termination Event. There shall not have occurred any event or condition that would permit CF&Co to terminate this Agreement pursuant to Section 11. 
 9. Indemnification and Contribution. 

(a) Company Indemnification. The Company agrees to indemnify and hold harmless CF&Co, the directors,
officers, partners, employees and agents of CF&Co and each person, if 

  
 23 

 
any, who (i) controls CF&Co within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, or (ii) is controlled by or is under common control
with CF&Co (a “CF&Co Affiliate”) from and against any and all losses, claims, liabilities, expenses and damages (including, but not limited to, any and all reasonable investigative, legal and other expenses incurred
in connection with, and any and all amounts paid in settlement (in accordance with Section 9(c)) of, any action, suit or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified party and any
third party, or otherwise, or any claim asserted), as and when incurred, to which CF&Co, or any such person, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or
otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly, on any untrue statement or alleged untrue statement of a material fact contained in the Registration Statements or the
Prospectus, or any amendments thereto (including the information deemed to be a part of each Registration Statement at the time of effectiveness and at any subsequent time pursuant to Rules 430A and 430B, if applicable) or the omission or alleged
omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that this indemnity agreement shall not apply to the extent that such loss, claim,
liability, expense or damage arises from or is caused directly or indirectly by an untrue statement or omission or alleged untrue statement or omission made in reliance on and in conformity with information furnished in writing to the Company by or
on behalf of CF&Co expressly for inclusion in the Registration Statements or Prospectus. This indemnity agreement will be in addition to any liability that the Company might otherwise have. 

(b) CF&Co Indemnification. CF&Co agrees to indemnify and hold harmless the Company and its directors
and each officer of the Company who signed the Registration Statements, and each person, if any, who (i) controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is
controlled by or is under common control with the Company (a “Company Affiliate”) against any and all losses, liabilities, claims, damages and expenses to which the Company, or any such person, may become subject under the
Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, as and when incurred, but only insofar as such loss, liability, claim, damage or expense arises from or is caused directly or
indirectly by an untrue statement or omission or alleged untrue statement or omission made in reliance on and in conformity with information furnished in writing to the Company by or on behalf of CF&Co expressly for inclusion in the Registration
Statements or Prospectus. 
 (c) Procedure. Any party that proposes to assert the right to be
indemnified under this Section 9 will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section 9,
notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might
have to any indemnified party otherwise than under this Section 9 and (ii) any liability that it may have to any indemnified party under the foregoing provision of this Section 9 unless, and only to the extent that, such
omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies 

  
 24 

 
the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party
promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified
party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided below. The
indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the
indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on the written advice of counsel) that there may be legal defenses available to it or other indemnified
parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on the written advice of counsel to the indemnified party) between the indemnified party and the
indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of
such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is
understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm
admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred. An indemnifying party
will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry
of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent
includes an unconditional release of each indemnified party from all liability arising or that may arise out of such claim, action or proceeding. 
 (d) Contribution. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this Section 9
is applicable in accordance with its terms but for any reason is held to be unavailable from the Company or CF&Co, the Company and CF&Co will contribute to the total losses, claims, liabilities, expenses and damages (including any
investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons
other than CF&Co, if any), to which the Company and CF&Co may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and CF&Co, on the other. The relative benefits
received by the Company on the one hand and CF&Co on the other hand shall be deemed to be in the same proportion as the total net proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the
total compensation received 

  
 25 

 
by CF&Co from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of
contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and CF&Co, on the other, with respect to
the statements or omission that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or CF&Co, on the
other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and CF&Co agree that it would not be just and equitable if contributions pursuant
to this Section 9(d) were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as
a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section 9(d) shall be deemed to include, for the purpose of this Section 9(d), any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with Section 9(c) hereof. Notwithstanding the foregoing provisions of this
Section 9(d), CF&Co shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 9(d), any person who controls a party to this Agreement within the meaning of
the Securities Act, and any officers, directors, partners, employees or agents of CF&Co, will have the same rights to contribution as that party, and each trustee of the Company and each officer of the Company who signed the Registration
Statements will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of
which a claim for contribution may be made under this Section 9(d), will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution
may be sought from any other obligation it or they may have under this Section 9(d) except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom
contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section 9(c) hereof, no party will be liable for contribution with respect to any action or claim settled without its written consent if such
consent is required pursuant to Section 9(c) hereof. 
 10. Representations and Agreements to Survive
Delivery. All representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of CF&Co, any
controlling persons, or the Company (or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement. 

  
 26 

 11. Termination. 

(a) Termination; General. CF&Co may terminate this Agreement, by notice to the Company, as hereinafter
specified at any time (1) if there has been, since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any change, or any development or event involving a prospective change, which
individually or in the aggregate, in the sole judgment of CF&Co has or could have a Material Adverse Effect and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares,
(2) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or
development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of CF&Co, impracticable or inadvisable to market the
Placement Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in the Placement Shares has been suspended or limited by the Commission or the Exchange, or if trading generally on the Exchange has been suspended or
limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market shall have occurred and be continuing, (5) if a
major disruption of securities settlements or clearance services in the United States shall have occurred and be continuing, or (6) if a banking moratorium has been declared by either U.S. Federal or New York authorities. 

(b) Termination by the Company. The Company shall have the right to terminate this Agreement in its sole
discretion at any time after the date of this Agreement. 
 (c) Termination by CF&Co.
CF&Co shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. 

(d) Automatic Termination. Unless earlier terminated pursuant to this Section 11, this Agreement shall
automatically terminate upon the issuance and sale of the Maximum Amount of Placement Shares through CF&Co pursuant to this Agreement. 
 (e) Continued Force and Effect. This Agreement shall remain in full force and effect unless terminated pursuant to Sections 8(k), 11(a), (b), (c), or (d) above or otherwise by
mutual agreement of the parties. 
 (f) Effectiveness of Termination. Any termination of this
Agreement shall be effective on the date specified in such notice of termination; provided, however, that such termination shall not be effective until the close of business on the date specified in such notice by CF&Co or the
Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement. 

(g) Liabilities. If this Agreement is terminated pursuant to Section 8(k) or this
Section 11, such termination shall be without liability of any party to any other party except as provided in Section 7(g) hereof, and except that, in the case of any termination of this

  
 27 

 
Agreement, Section 9, Section 16 and Section 17 hereof, and the obligation herein to pay any discount, commission or other compensation accrued but unpaid,
shall survive such termination and remain in full force and effect. 
 12. Notices. All notices or other
communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to CF&Co, shall be delivered to Cantor
Fitzgerald & Co., 499 Park Avenue, New York, New York 10022, fax no. (212) 308-3730, Attention: Capital Markets/Jeff Lumby, with copies to Stephen Merkel, General Counsel, at the same address, and Reed Smith LLP, 599 Lexington Avenue,
New York, New York 10022, fax no. (212) 521-5450, Attention: Daniel I. Goldberg; or if sent to the Company, shall be delivered to Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080, fax no.
(650) 266-3505, Attention: Chief Financial Officer, with a copy to Cooley LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA 94306, fax no. (650) 849-7400, Attention: Suzanne Sawochka Hooper. Each party to this Agreement may
change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile
transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to a
nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement,
“Business Day” shall mean any day on which the Exchange and commercial banks in the City of New York are open for business. 
 13. Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and CF&Co and their respective successors and the affiliates, controlling persons,
officers and directors referred to in Section 9 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in
this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party. 
 14. Adjustments for Stock Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any stock split, stock
dividend or similar event effected with respect to the Placement Shares. 
 15. Entire Agreement; Amendment;
Severability. This Agreement (including all schedules and exhibits attached hereto and placement notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and CF&Co. In the event that any
one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to
the fullest possible extent that it is valid, legal and enforceable, and the 

  
 28 

 
remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect
to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. 
 16. APPLICABLE LAW; CONSENT TO JURISDICTION. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE
PRINCIPLES OF CONFLICTS OF LAWS. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION
OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR
PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF
PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. 
 17. WAIVER OF JURY TRIAL. THE COMPANY AND CF&CO EACH HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON OR ARISING OUT OF THIS
AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 
 18. Counterparts. This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile transmission. 

19. Definitions. As used in this Agreement, the following terms have the respective meanings set forth below: 

(a) “Applicable Time” means the date of this Agreement, each Representation Date, the date on
which a Placement Notice is given, any date on which Placement Shares are sold hereunder, or such other time as agreed to by the Company and CF&Co. 
 (b) “Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433, relating to the Placement Shares that (1) is
required to be filed with the Commission by the Company, (2) is a “road show” that is a “written communication” within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or

  
 29 

 
(3) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not reflect the final terms, and all free
writing prospectuses that are listed in Exhibit G hereto, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule
433(g) under the Securities Act. 
 (c) “Rule 433” means Rule 433 of the Securities
Act. 
 All references in this Agreement to financial statements and schedules and other information that is
“contained,” “included” or “stated” in the Registration Statements or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other
information that is incorporated by reference in the Registration Statements or the Prospectus, as the case may be. 
 All
references in this Agreement to the Registration Statements, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to IDEA; all references in this Agreement to
any Issuer Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to
IDEA; and all references in this Agreement to “supplements” to the Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials prepared in connection with any offering, sale or private placement
of any Placement Shares by CF&Co outside of the United States. 
 20. Permitted Free Writing Prospectuses. The
Company represents, warrants and agrees that, unless it obtains the prior consent of CF&Co, and CF&Co represents, warrants and agrees that, unless it obtains the prior consent of the Company, it has not made and will not make any offer
relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a “free writing prospectus,” as defined in Rule 405, required to be filed with the Commission. Any such free
writing prospectus consented to by CF&Co or by the Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company represents and warrants that it has treated and agrees that
it will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing
Prospectus, including timely filing with the Commission where required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free writing prospectuses, if any, listed in Exhibit G hereto are
Permitted Free Writing Prospectuses. 
 21. Absence of Fiduciary Relationship. The Company acknowledges and agrees
that: 
 (a) CF&Co has been retained solely to act as underwriter in connection with the sale of the
Placement Shares and that no fiduciary, advisory or agency relationship between the Company and CF&Co has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether CF&Co has advised or is
advising the Company on other matters; 
 (b) the Company is capable of evaluating and understanding and
understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; 

  
 30 

 (c) the Company has been advised that CF&Co and its affiliates are
engaged in a broad range of transactions which may involve interests that differ from those of the Company and that CF&Co has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency
relationship; 
 (d) CF&Co has not provided any legal, accounting, regulatory or tax advice with respect
to the transactions contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate; and 

(e) the Company waives, to the fullest extent permitted by law, any claims it may have against CF&Co, for breach
of fiduciary duty or alleged breach of fiduciary duty and agrees that CF&Co shall have no liability (whether direct or indirect) to the Company in respect to such fiduciary claim or to any person asserting a fiduciary duty claim on behalf of or
in right of the Company, including shareholders, partners, employees or creditors of the Company. 
 [Remainder of Page
Intentionally Blank] 

  
 31 

 If the foregoing correctly sets forth the understanding between the Company and CF&Co,
please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and CF&Co. 
             Very truly yours, 
  

			
	SUNESIS PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Eric H. Bjerkholt

	Name:	 	Eric H. Bjerkholt
	Title:	 	Senior Vice President, Corporate Development and Finance, and Chief Financial Officer

  

			
	ACCEPTED as of the date first-above written:
	
	CANTOR FITZGERALD & CO.
		
	By:	 	 /s/ Jeffrey Lumby

	Name:	 	Jeffrey Lumby
	Title:	 	Managing Director

 [Signature page to Sales Agreement] 

 SCHEDULE 1 

FORM OF PLACEMENT NOTICE* 
  

							
	From:	 	[	    	]	  	
	Cc:	 	[	    	]	  	
	To:	 	[	    	]	  	

 Subject:        Controlled Equity Offering—Placement Notice 

Gentlemen: 
 Pursuant to
the terms and subject to the conditions contained in the Controlled Equity OfferingSM Sales Agreement between Sunesis Pharmaceuticals, Inc. (the “Company”) and Cantor Fitzgerald & Co. (“CF&Co”), dated August 11, 2011 (the “Agreement”), I
hereby request on behalf of the Company that CF&Co sell up to [ ] shares of the Company’s Common Stock, par value $0.0001 per share, at a minimum market price of
$                 per share. 
 [The Company may
include such other sales parameters at it deems appropriate.] 

 SCHEDULE 2 
 CANTOR FITZGERALD & CO. 
 Jeff Lumby 

Josh Feldman 
 Peter Dippolito 

SUNESIS PHARMACEUTICALS, INC. 

Daniel N. Swisher, Jr. 
 Eric H. Bjerkholt

 SCHEDULE 3 

COMPENSATION 

CF&Co shall be paid compensation of 3% of the gross proceeds from the sales of the Placement Shares. 

 Exhibit 7(m) 

OFFICER CERTIFICATE 
 The undersigned, the duly qualified and elected
                                         
   , of SUNESIS PHARMACEUTICALS, INC. (“Company”), a Delaware corporation, does hereby certify in such capacity and on behalf of the Company, pursuant to Section 7(m) of the Sales
Agreement, dated August 11, 2011 (the “Sales Agreement”), between the Company and Cantor Fitzgerald & Co., that to the best of the knowledge of the undersigned. 

(i) The representations and warranties of the Company in Section 5 of the Sales Agreement (A) to the extent such
representations and warranties are subject to qualifications and exceptions contained therein relation to materiality or Material Adverse Effect, are true and correct on and as of the date hereof, except for those representations and warranties that
speak solely as of a specific date and which were true and correct as of such date, with the same force and effect as if expressly made on and as of the date hereof and (B) to the extent such representations and warranties are not subject to
any qualifications or exceptions, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof except for those representations and warranties that speak solely as of a specific date and which were true
and correct as of such date, with the same force and effect as if expressly made on and as of the date hereof; and 
 (ii) The
Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof. 

 

			
	 By:
	 	  

		 	 Name:

		 	 Title:

Date:Form of Transition Services Agreement

 Exhibit 10.1 
 TRANSITION SERVICES AGREEMENT 
 (H&S TO BEAM) 

This TRANSITION SERVICES AGREEMENT, dated as of
[                ], 2011 (this “Agreement”), is by and between Fortune Brands, Inc., a Delaware corporation (“Fortune Brands” or
“Beam”), and Fortune Brands Home & Security, Inc., a Delaware corporation (“H&S”). 
 W I T N E S S E T H 
 WHEREAS, subject to the terms and conditions of that certain
Separation and Distribution Agreement, dated as of [                ], 2011 (the “Separation and Distribution Agreement”), by and between Fortune Brands
and H&S, Fortune Brands has agreed to distribute to holders of shares of Fortune Brands common stock, par value $3.125 per share, all of the outstanding shares of H&S common stock, par value $0.01 per share, owned by Fortune Brands as of the
Distribution Date (as defined in the Separation and Distribution Agreement); 
 WHEREAS, the Separation and Distribution
Agreement contemplates that Fortune Brands will change its name to “Beam Inc.” following such distribution; and 

WHEREAS, following such distribution, Beam desires to receive, and H&S is willing to provide, or cause to be provided, for a limited
period of time, certain transition services in connection with Beam’s operation of its business after the Distribution Date, subject to the terms and conditions of this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements and covenants set forth herein, the parties hereto hereby
agree as follows: 
 ARTICLE I 
 DEFINITIONS AND INTERPRETATION 
 SECTION 1.1
Definitions. Capitalized terms used but not defined in this Agreement shall have the meanings ascribed to such terms in the Separation and Distribution Agreement. For purposes of this Agreement, the following terms shall have the
following meanings: 
 (a) “Beam Parties” means Beam and its Subsidiaries (including those formed or
acquired after the date hereof), other than the H&S Parties; 
 (b) “Business Day” means any
calendar day that is not a Saturday, Sunday or legal holiday in New York City; and 
 (c) “H&S
Parties” means H&S, the H&S Subsidiaries, the Transferred Subsidiaries and any other Subsidiary of H&S (including those formed or acquired after the date hereof). 

SECTION 1.2 Interpretation. The headings of Sections contained in this Agreement have been inserted for convenience
of reference only and shall not be deemed to be a part of or 

 
to affect the meaning or interpretation of this Agreement. In this Agreement, (i) the words “include,” “includes” and “including” shall be deemed to be followed
by the words “without limitation;” (ii) the word “or” is not exclusive and (iii) the words “herein,” “hereunder,” “hereof,” “hereto” and words of similar import shall be deemed to
be references to this Agreement as a whole and not to any particular Section or other provision hereof. Unless the context clearly indicates otherwise, (a) words used in the singular include the plural and words used in the plural include the
singular; (b) reference to any Section or Schedule means such Section of, or such Schedule to, this Agreement, as the case may be; and (c) reference to any agreement, instrument or other document means such agreement, instrument or other
document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and by this Agreement. This Agreement shall be construed without regard to any presumption or rule requiring construction or
interpretation against the party drafting an instrument or causing any instrument to be drafted. 
 ARTICLE II 

SERVICES 

SECTION 2.1 Provision of Services. 
 (a) Subject to the terms and conditions of this Agreement, H&S shall provide, or cause to be provided, to the Beam Parties, solely for the benefit of the Fortune Brands Business in the ordinary course
of business, the services described on Schedule A (the “Services”), the terms of which are incorporated herein by reference. No Beam Party shall resell, subcontract, license, sublicense or otherwise transfer any of the
Services to any Person whatsoever or permit use of any of the Services by any Person other than by the Beam Parties directly in connection with the conduct of the Fortune Brands Business in the ordinary course of business. H&S shall exercise
reasonable care to ensure that the manner in which it performs or provides the Services does not have any adverse effect on the name, trading image, goodwill or business of any Beam Party. 

SECTION 2.2 Additional Services. If, following the Distribution Date, it shall come to the notice of Beam that any
service or facility provided by any H&S Party prior to the Distribution Date to or for any Beam Party and not covered hereby is not being performed or made available after the Distribution Date and Beam considers that the relevant service or
facility is necessary or desirable for the effective operation of its business, it may notify H&S giving full details of the relevant service or facility, and H&S and Beam shall cooperate and negotiate in good faith to the extent reasonably
practicable with a view to such service or facility being provided on reasonable commercial terms. 
 SECTION 2.3
Standard of Performance; Priority. 
 (a) H&S shall use commercially reasonable efforts to provide, or
cause to be provided, to the Beam Parties, each Service in a manner generally consistent with the manner and level of care with which such Service was provided to the Beam Parties immediately prior to the Distribution Date (or, with respect to any
Service not provided by any H&S Party to any Beam Party prior to the Distribution Date, generally consistent with the manner and level of care with which such Service is performed by any H&S Party on behalf of any other H&S Party),

  
 2 

 
unless otherwise specified in this Agreement or Schedule A. Notwithstanding the foregoing, H&S shall have no obligation hereunder to provide to any Beam Party (i) any
improvements, upgrades, updates, substitutions, modifications or enhancements to any of the Services unless otherwise specified on Schedule A or (ii) any Service to the extent that the need for such Service arises, directly or
indirectly, from the acquisition by any Beam Party, outside the ordinary course of business, of any assets of, or any equity interest in, any Person. 
 (b) H&S shall use commercially reasonable efforts not to establish priorities in favor of the H&S Parties, on the one hand, and to the detriment of the Beam Parties, on the other hand, as to the
provision of any Service solely based on the fact that the Beam Parties are no longer affiliated with H&S, and H&S shall use commercially reasonable efforts to provide the Services, or cause the Services to be provided, within a time frame
so as not to materially disrupt the Fortune Brands Business. Notwithstanding the foregoing, Beam acknowledges and agrees that one or more of the H&S Parties may be providing to other H&S Parties services similar to the Services provided
hereunder, or services that involve the same resources as those used to provide the Services, and that H&S shall have the right to establish reasonable priorities as between the H&S Parties, on the one hand, and the Beam Parties, on the
other hand, as to the provision of any Service if H&S determines that such priorities are necessary to avoid any adverse effect on any of the H&S Parties. If any such priorities are established, H&S shall advise Beam as soon as
reasonably possible of any Services that will be delayed as a result of such prioritization and will use commercially reasonable efforts to minimize the duration and impact of such delays. 

(c) Unless otherwise specifically set forth on Schedule A, the Beam Parties’ use of the Services shall be consistent with
past practice. 
 (d) Notwithstanding anything to the contrary contained herein, in no event shall any Service include
(i) any service that would be or otherwise becomes unlawful for H&S to provide or (ii) the exercise of business judgment or general management for any Beam Party. 

SECTION 2.4 H&S Employees Performing Services. Notwithstanding anything to the contrary contained in
Section 2.1 (but subject to the last sentence of this Section 2.4), H&S shall have the exclusive right to select, employ, pay, supervise, administer, direct and discharge any of its employees who perform the Services.
H&S shall be responsible for paying such employees’ compensation and providing to such employees any benefits. With respect to each Service, H&S shall use commercially reasonable efforts to have qualified individuals participate in the
provision of such Service; provided, however, that (a) H&S shall not be obligated to have any individual participate in the provision of any Service if H&S determines that such participation would adversely affect any
H&S Party and (b) no H&S Party shall be required to continue to employ any particular individual during the applicable Service Period. 
 SECTION 2.5 Compliance with Law. Each party hereto shall, and shall cause each of its Affiliates to, comply with all applicable laws, rules, ordinances and regulations of any
governmental entity or regulatory agency governing the Services to be provided hereunder. Neither party hereto shall take, or permit any of its Affiliates to take, any action in violation of any applicable law, rule, ordinance or regulation that
could result in liability being imposed on the other party hereto or any of such other party’s Affiliates. 

  
 3 

 SECTION 2.6 Temporary Nature of Services. Beam acknowledges that the purpose
of this Agreement is to enable it to receive the Services on an interim basis. Accordingly, at all times from and after the Distribution Date, Beam shall use commercially reasonable efforts to (a) make or obtain, or cause to be made or
obtained, any filings, registrations, approvals, permits or licenses; (b) implement, or cause to be implemented, any systems; (c) purchase, or cause to be purchased, any equipment; and (d) take, or cause to be taken, any and all other
actions, in each case necessary or advisable to enable Beam or an Affiliate thereof to provide the Services for the relevant Beam Parties as soon as reasonably practicable, and in any event prior to the expiration of the relevant Service Periods.
For the avoidance of doubt, Beam acknowledges and agrees that H&S shall not be required to provide any Service for a period longer than the applicable Service Period. 
 ARTICLE III 
 FEES AND PAYMENTS 

SECTION 3.1 Fees for the Services. 
 (a) As compensation for the Services, Beam agrees to pay H&S, in accordance with this Agreement, all amounts as set forth on Schedule A and in Section 3.1(b). Except as otherwise
provided in this Agreement, the amount of any monthly service fee shall be prorated in the event that the corresponding Services were provided for only a portion of a given month. 

(b) In addition to the compensation set forth on Schedule A, H&S shall be entitled to reimbursement for reasonable and
customary out-of-pocket expenses incurred in connection with the performance of the Services pursuant to this Agreement. 

SECTION 3.2 Invoices. 
 (a) H&S shall submit statements of account to Beam within ten (10) days after the end of each month with respect to all amounts payable by Beam to H&S hereunder (the “Invoiced
Amount”), setting out the Services provided by reference to Schedule A and the amount billed to Beam as a result of providing such Services (together with, in arrears, any Commingled Invoice Statements (as defined below) and any
other invoices for Services provided by third parties, in each case setting out the Services provided by the applicable third parties by reference to Schedule A). 
 (b) H&S may cause any third-party service provider to which amounts are payable by or for the account of Beam in connection with the Services to issue a separate invoice to Beam for such amounts. Beam
shall pay or cause to be paid any such separate third-party invoice in accordance with the payment terms thereof. Any third-party invoices that aggregate Services for the benefit of the Beam Parties, on the one hand, with services not for the
benefit of the Beam Parties, on the other hand (each, a “Commingled Invoice”), shall be separated by H&S. H&S shall prepare a statement indicating that portion of the invoiced amount of such Commingled Invoice that is
attributable to Services rendered for the benefit of the Beam Parties (the “Commingled Invoice Statement”). As promptly as practicable after the preparation thereof, H&S shall deliver such Commingled Invoice Statement and a copy
of the Commingled Invoice to Beam. H&S shall not be required to use its own funds for payments to any third-party service 

  
 4 

 
provider providing any of the Services or to satisfy any payment obligation of any Beam Party to any third-party service provider; provided, however, that in the event H&S does
use its own funds for any such payments to any third-party service provider, Beam shall reimburse H&S for such payments as invoiced by H&S within thirty (30) days following the date of delivery of such invoice from H&S. 

SECTION 3.3 Invoice Disputes. In the event that Beam in good faith disputes an invoice submitted by H&S, Beam
may withhold payment of any amount subject to the dispute; provided, however, that (a) Beam will continue to pay all undisputed amounts in accordance with the terms hereof and (b) Beam will notify H&S, in writing, of any
disputed amounts and the reason for any dispute by the due date for payment of the invoice containing any disputed amounts. In the event of a dispute regarding the amount of any invoice, or portion thereof, the parties hereto will use all reasonable
efforts to resolve such dispute within thirty (30) days after Beam delivers written notification of such dispute to H&S. Each party hereto will provide full supporting documentation concerning any disputed amount or invoice within thirty
(30) days after Beam delivers written notification of the dispute. Unpaid fees that are under good faith dispute will not be considered a basis for default hereunder. To the extent that a dispute regarding the amount of any invoice cannot be
resolved pursuant to this Section 3.3, the dispute resolution procedures set forth in Section 7.1 shall apply. 
 SECTION 3.4 Time of Payment. 
 (a) Subject to
Section 3.4(b), Beam shall pay the Invoiced Amount to H&S in United States dollars by wire transfer of immediately available funds to an account specified by H&S in the relevant invoice, or in such other manner as specified by
H&S in writing, within thirty (30) days after the date of delivery to Beam of the applicable statement of account; provided, however, that in the event that Beam, in good faith and upon reasonable grounds disputes any invoiced
item in accordance with Section 3.3, payment of such item may be made after resolution of such dispute. 
 (b)
Unless H&S and Beam otherwise agree in writing, where Services are provided to a Beam Party outside of the United States by a Person located in the same country, amounts shall be billed and paid in the local currency of the entity providing the
Services. Unless H&S and Beam otherwise agree in writing, if payments are to be made between legal entities not within the same country, such amounts shall be billed and paid in United States dollars. To the extent necessary, local currency
conversion shall be based on H&S’s internal exchange rate for the then-current month. 
 (c) In the event that Beam
does not make any payment required under the provisions of this Agreement to H&S when due in accordance with the terms hereof, H&S shall, at its option, charge Beam interest on the unpaid amount at the prime rate charged by JPMorgan Chase
Bank, N.A. (or its successor). In addition, Beam shall reimburse H&S for all costs of collection of overdue amounts, including any reimbursement required under Section 3.2(b) and any reasonable attorneys’ fees. 

(d) Beam shall, within thirty (30) days after the date of delivery to Beam of any Commingled Invoice Statement, pay or cause to be
paid the amount set forth on such 

  
 5 

 
Commingled Invoice Statement to the third-party service provider and shall concurrently deliver evidence of such payment to H&S. Beam acknowledges and agrees that it shall be responsible for
any interest or other amounts in respect of any portion of any Commingled Invoice that Beam is required to pay pursuant to any Commingled Invoice Statement. 
 SECTION 3.5 Taxes. Any amounts payable under this Agreement are exclusive of any goods and services taxes, value added taxes, sales taxes or similar taxes (collectively,
“Sales Taxes”) now or hereinafter imposed on the performance or delivery of Services, and an amount equal to such Sales Taxes so chargeable shall, subject to receipt of a valid receipt or invoice as required below in this
Section 3.5, be paid by Beam to H&S in addition to the amounts otherwise payable under this Agreement. In each case where an amount in respect of Sales Tax is payable by Beam in respect of a Service provided by any H&S Party,
H&S shall furnish in a timely manner a valid Sales Tax receipt or invoice to Beam in the form and manner required by applicable law to allow Beam to recover such Sales Tax to the extent allowable under such law. The parties hereto agree to use
commercially reasonable efforts to cooperate to minimize any Sales Tax payable with respect to the Services. 
 ARTICLE IV

 TERM AND TERMINATION 
 SECTION 4.1 Term. The performance of the Services under this Agreement shall commence on the Distribution Date and shall continue with respect to each Service until the relevant date
set forth on Schedule A with respect to such Service (each, a “Service Period”), unless such period is earlier terminated in accordance with the terms hereof. 

SECTION 4.2 Termination by Beam. 
 (a) Beam will have no obligation to continue to use any of the Services and, except as otherwise specified on Schedule A, Beam may terminate any Service by giving H&S at least thirty
(30) days’ prior written notice of Beam’s desire to terminate such Service. To the extent possible, Beam will give such notice at the beginning of a month to terminate the Service as of the beginning of the next month to avoid the
need to prorate any monthly payment charges. As soon as reasonably practicable following receipt of any such notice, H&S will advise Beam in writing as to whether termination of such Service will (i) require the termination or partial
termination of, or otherwise affect the provision of, any other Services or (ii) result in any early termination costs (which will be limited to costs that H&S actually incurs). If either will be the case, Beam may withdraw its termination
notice within five (5) Business Days after the receipt of such notice from H&S. If Beam does not withdraw the termination notice within such period, such termination will be final. Upon such termination, Beam’s obligation to pay for
such Service(s) will terminate, and H&S will cease, or cause its Affiliates or third-party service providers to cease, providing the terminated Service(s); provided, however, that Beam shall reimburse H&S for the reasonable
termination costs actually incurred by H&S resulting from Beam’s early termination of such Services, including those owed to third-party service providers. H&S shall use commercially reasonable efforts to mitigate such termination
costs. 
 (b) Beam may terminate this Agreement as of the end of any month provided that (i) Beam has given H&S at
least thirty (30) days prior written notice and (ii) Beam reimburses H&S 

  
 6 

 
for any reasonable out-of-pocket expenses or costs actually incurred by H&S due to such termination. 
 SECTION 4.3 Termination for Breach. Either party hereto shall have, in addition to any other rights and remedies such party may have, the right to terminate this Agreement on thirty
(30) days’ prior written notice to the other party hereto, if such other party shall have materially breached or defaulted in the performance of any provision of this Agreement; provided, however, that if it is possible for
such breach or default to be cured and the party receiving such notice of termination shall cure such breach or default within thirty (30) days after receipt of such notice, then this Agreement shall continue in full force and effect and
provided further that such termination shall only apply to those Services in respect of which the defaulting party is in material breach and shall be without prejudice to the provision or receipt of all other Services, which shall
remain in full force and effect notwithstanding such termination. 
 SECTION 4.4 Termination for
Insolvency. Either party hereto shall have the right, notwithstanding any other provisions of this Agreement, and in addition to any other rights and remedies such party may have, to terminate this Agreement forthwith and at any time if:
(a) the other party hereto becomes insolvent; (b) the other party hereto files a petition in bankruptcy or insolvency; (c) the other party hereto is adjudicated bankrupt or insolvent; (d) the other party hereto files any petition
or answer seeking reorganization, readjustment or arrangement of such other party’s business under any law relating to bankruptcy or insolvency; (e) a receiver, trustee or liquidator is appointed for any of the property of the other party
hereto and within sixty (60) days thereof such other party fails to secure a dismissal thereof; (f) the other party hereto makes any assignment for the benefit of creditors; or (g) there is a government expropriation of any material
portion of the assets of the other party hereto. 
 SECTION 4.5 Effect of Termination. 

(a) In any event, no termination, cancelation or expiration of this Agreement shall prejudice the right of either party hereto to recover
any payment due at the time of termination, cancelation or expiration (or any payment accruing as a result thereof), nor shall it prejudice any cause of action or claim of either party hereto accrued or to accrue by reason of any breach or default
by the other party hereto. 
 (b) Survival. Notwithstanding anything to the contrary contained herein, this
Section 4.5(b), Section 5.2, Article III, Article VI and Article VII of this Agreement shall survive the termination of this Agreement. 

ARTICLE V 

INTELLECTUAL PROPERTY, COOPERATION AND CONFIDENTIALITY 
 SECTION 5.1 Cooperation; Access. 
 (a) Beam shall, and shall
cause each of the Beam Parties to, permit H&S and its employees and representatives access, on Business Days during hours that constitute regular business hours for Beam and upon reasonable prior request, to the premises of the Beam Parties and
such data, books, records and personnel designated by Beam and the Beam Parties as involved in receiving or overseeing the Services as H&S may reasonably request for the 

  
 7 

 
purposes of providing the Services. H&S shall provide Beam, upon reasonable prior written notice, such documentation relating to the provision of the Services as Beam may reasonably request
for the purposes of confirming any Invoiced Amount or other amount payable pursuant to any Commingled Invoice Statement or otherwise pursuant to this Agreement. Any documentation so provided to H&S pursuant to this Section 5.1(a)
shall be subject to the confidentiality obligations set forth in Section 5.2. 
 (b) H&S shall provide the Beam
Parties with such advice, assistance and information in connection with the performance of the Services as Beam may from time to time reasonably require. H&S and Beam shall also liaise as appropriate to ensure that the Services are carried out
in accordance with the provisions of Schedule A hereto, and where reasonably, practicable H&S shall comply with any instructions that Beam shall reasonably issue from time to time concerning the manner in which the Services shall be
provided to the Beam Parties. 
 (c) Beam and H&S shall each use reasonable best efforts to keep each other informed of any
special requirements applicable to the carrying out of the Services. To the extent reasonably necessary and appropriate H&S shall promptly take steps where reasonably practicable to comply with such special requirements. In the event that these
steps shall result in any increase or reduction in the actual cost to H&S of providing the relevant Services then the fees payable pursuant to Section 3.1 shall be increased or reduced accordingly. 

SECTION 5.2 Confidentiality. Each party hereto agrees that it shall treat in confidence all documents, materials and
other information that it shall have obtained regarding the other party during the course of the performance of this Agreement and the transactions contemplated by this Agreement that the receiving party should reasonably recognize as being of a
confidential nature (“Confidential Information”). Confidential Information shall not be communicated to any third party (other than to the parties’ respective counsel, accountants, financial advisors, consultants or lenders or
employees who need to know such Confidential Information). No Person shall use any Confidential Information in any manner whatsoever except solely for the purpose of carrying out the transactions contemplated by this Agreement or as otherwise
contemplated by this Agreement. The obligation of each party to treat Confidential Information in confidence shall not apply to any information that (a) is on the date hereof in such party’s possession; provided that such
information is not known to such party to be subject to another confidentiality agreement with, or other obligation of secrecy to, the other party or any third party and such information may be disclosed pursuant to the Separation and Distribution
Agreement; (b) is on the date hereof or hereafter becomes available to the public other than as a result of a disclosure, directly or indirectly, by such party or its agents; (c) is on the date hereof or hereafter becomes available to such
party on a non-confidential basis from a source other than the other party or any of the other party’s agents; provided that (i) such source is not known by the receiving party to be subject to a confidentiality agreement with, or
other obligation of secrecy to, the disclosing party or any third party and (ii) such information may be disclosed pursuant to the Separation and Distribution Agreement or (d) can be shown by such party to have been independently developed
by such party and such information may be disclosed pursuant to the Separation and Distribution Agreement. The foregoing confidentiality and nondisclosure obligations shall not apply to the extent any such Confidential Information is required to be
disclosed by applicable law; provided that, in such event, the party required to disclose such information provides the other party with prompt advance notice of such required disclosure so

  
 8 

 
that such other party shall have the opportunity, if it so desires, to seek a protective order or other appropriate remedy. 

SECTION 5.3 Intellectual Property. Beam grants to the H&S Parties a limited, non-exclusive, fully paid-up,
nontransferable, revocable license, without the right to sublicense, for the term of this Agreement to use all intellectual property owned by or, to the extent permitted by the applicable license, licensed to Beam solely to the extent necessary for
the H&S Parties to perform the Services. 
 ARTICLE VI 

LIMITATION OF LIABILITY, INDEMNIFICATION AND REMEDIES 
 SECTION 6.1 No Warranty; Exclusive Remedy. 
 (a) H&S and
Beam both acknowledge and agree that H&S has agreed to provide or cause to be provided the Services hereunder as an accommodation to Beam. NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESSED OR IMPLIED (INCLUDING WARRANTIES OF
NON-INFRINGEMENT, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND CONFORMITY TO ANY REPRESENTATION OR DESCRIPTION), ARE MADE BY ANY OF THE H&S PARTIES WITH RESPECT TO THE PROVISION OF SERVICES UNDER THIS AGREEMENT AND, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ALL SUCH REPRESENTATIONS OR WARRANTIES ARE HEREBY WAIVED AND DISCLAIMED. 
 (b) Other than
in the event of fraud, willful misconduct, bad faith or gross negligence on the part of any H&S Party for which Beam shall have a right to seek indemnity hereunder (and without limiting the indemnification rights under
Section 6.3(b)), the sole and exclusive remedy of any Beam Party with respect to any and all Losses caused by or arising from the performance or non-performance of any Service by H&S (either directly or indirectly) will be the
termination of this Agreement in accordance with Section 4.2; provided, however, that, if capable of being performed or re-performed and if requested by Beam, H&S agrees to perform or re-perform, as applicable, or will
cause one or more of its Affiliates or third-party service providers to perform or re-perform, as applicable, any Service that does not comply with the requirements and level of service set forth on Schedule A and in Section 2.3.

 SECTION 6.2 Limitation of Liability. 

(a) EXCEPT AS PROVIDED IN SECTION 6.2(b), NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT TO THE CONTRARY, IN NO EVENT WILL
ANY H&S PARTY OR ANY BEAM PARTY BE LIABLE UNDER ANY CIRCUMSTANCES OR LEGAL THEORY FOR LOSSES RELATED TO INCONVENIENCE, DOWNTIME, INTEREST, COST OF CAPITAL, FRUSTRATION OF ECONOMIC OR BUSINESS EXPECTATIONS, LOST PROFITS, LOST REVENUES, LOST
SAVINGS, LOSS OF USE, TIME, DATA OR GOOD WILL, OR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL, COLLATERAL OR CONSEQUENTIAL DAMAGES, REGARDLESS OF WHETHER SUCH LOSSES ARE FORESEEABLE; PROVIDED, HOWEVER, THAT TO THE EXTENT AN INDEMNIFIED
PARTY IS REQUIRED TO PAY ANY LOSSES RELATED TO 

  
 9 

 
INCONVENIENCE, DOWNTIME, INTEREST, COST OF CAPITAL, FRUSTRATION OF ECONOMIC OR BUSINESS EXPECTATIONS, LOST PROFITS, LOST REVENUES, LOST SAVINGS, LOSS OF USE, TIME, DATA OR GOODWILL, OR ANY
SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL, COLLATERAL OR CONSEQUENTIAL DAMAGES TO A PERSON WHO IS NOT AN H&S PARTY OR A BEAM PARTY IN CONNECTION WITH A THIRD-PARTY CLAIM, SUCH LOSSES WILL CONSTITUTE DIRECT LOSSES NOT SUBJECT TO THE LIMITATION SET
FORTH IN THIS SECTION 6.2(a). 
 (b) The limitations set forth in Section 6.2(a) shall not apply to Losses
that arise as the result of fraud, willful misconduct, bad faith or gross negligence of H&S, Beam or anyone performing Services pursuant to this Agreement. 
 SECTION 6.3 Indemnification. Notwithstanding anything to the contrary contained in this Agreement and without limiting the indemnification rights of the parties hereto set forth in
the Separation and Distribution Agreement: 
 (a) except insofar as the claim, demand, suit or recovery relates to fraud,
willful misconduct, bad faith or gross negligence of any H&S Party, Beam will, and will cause its Affiliates to, indemnify and hold harmless the H&S Parties and their respective employees, officers, directors and agents (collectively, the
“H&S Indemnified Parties”) from and against any Losses (including reasonable expenses of investigation and attorneys’ fees incurred or suffered by the H&S Indemnified Parties) arising out of any claim made against any
H&S Party by a third party to the extent caused by or resulting from any of the Services rendered pursuant to the terms of this Agreement; provided, however, that the foregoing will not limit the indemnification obligations of
H&S under Section 6.3(b); and 
 (b) except insofar as the claim, demand, suit or recovery relates to fraud,
willful misconduct, bad faith or gross negligence of any Beam Party, H&S will, and will cause its Affiliates to, indemnify and hold harmless the Beam Parties and their respective employees, officers, directors and agents (collectively, the
“Beam Indemnified Parties”) from and against any Losses (including reasonable expenses of investigation and attorneys’ fees incurred or suffered by the Beam Indemnified Parties) arising out of the performance of any Service by
a third-party service provider on behalf of H&S, but only to the extent H&S is indemnified or otherwise compensated by such third-party service provider for any breach of its obligations to H&S with respect to the provision of such
Service and, in such event, only on a pro rata basis taking into account all H&S Parties similarly affected. 

SECTION 6.4 Remedies. The parties hereto agree that irreparable damage may occur in the event that any provision of this
Agreement is not performed in accordance with its specific terms or is otherwise breached. It is accordingly agreed that each of the parties hereto shall be entitled to equitable relief to prevent or remedy breaches of this Agreement, without proof
of actual damages and without the necessity of posting a bond, including in the form of an injunction or injunctions or orders for specific performance in respect of such breaches. 

  
 10 

 ARTICLE VII 
 MISCELLANEOUS 
 SECTION 7.1 Dispute Resolution.
Executive officers of each of H&S and Beam will meet as expeditiously as possible to resolve any dispute directly or indirectly arising out of or in relation to this Agreement or the validity, interpretation, construction, performance, breach or
enforceability of this Agreement, and any dispute that is not so resolved within thirty (30) days shall be resolved in accordance with the provisions of Section 12.2 of the Separation and Distribution Agreement, which shall apply
mutatis mutandis to this Agreement. 
 SECTION 7.2 Assignment. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and permitted assigns. No party hereto may assign any of its rights or delegate any of its obligations under this Agreement without the written consent of the other
party hereto, which consent may be withheld in such other party’s sole and absolute discretion and any assignment or attempted assignment in violation of the foregoing will be null and void; provided, however, that H&S may
delegate its duties hereunder to such Affiliates or third-party service providers as may be qualified to provide the Services and provided further that H&S has provided at least forty-five (45) days’ advance written
notice to Beam prior to any such delegation of any duties hereunder, and in the event Beam reasonably objects to any such delegation, H&S will reasonably assist in the process of transitioning such service to Beam or Beam’s designee prior
to, and in lieu of, any such delegation. 
 SECTION 7.3 Relationship of the Parties. The parties hereto are
independent contractors, and neither party hereto is an employee, partner or joint venturer of the other. Under no circumstances shall any of the employees of a party hereto be deemed to be employees of the other party hereto for any purpose.
Neither party hereto shall have the right to bind the other to any agreement with a third party nor to represent itself as a partner or joint venturer of the other by reason of this Agreement. 

SECTION 7.4 Third-Party Beneficiaries. Except for Section 6.3, this Agreement is solely for the benefit of the parties
hereto and their respective successors and permitted assigns, and nothing herein express or implied shall give or be construed to give to any other Person any legal or equitable rights hereunder. 

SECTION 7.5 Force Majeure. Neither party hereto shall be in default of this Agreement by reason of its delay in the
performance of, or failure to perform, any of its obligations hereunder (other than the payment of money) if such delay or failure is caused by acts of God, acts of civil or military authority, embargoes, acts of terrorism, epidemics, war, riots,
insurrections, fires, explosions, earthquakes, floods, unusually severe weather conditions, labor problems or unavailability of parts, or, in the case of computer systems, any failure in electrical or air conditioning equipment or other events that
arise from circumstances beyond the reasonable control of such party. In the event of any such excused delay, the rime for performance shall be extended for a period equal to the time lost by reason of the delay. 

SECTION 7.6 Miscellaneous. Except as otherwise expressly set forth in this Agreement, the provisions of Article
XII of the Separation and Distribution Agreement other 

  
 11 

 
than the provisions thereof relating to assignability, third-party beneficiaries, force majeure and termination shall apply mutatis mutandis to this Agreement. 

* * * * * * * 

  
 12 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	FORTUNE BRANDS, INC.
		
	By:	 	  

		 	Name:
		 	Title:
	
	FORTUNE BRANDS HOME & SECURITY, INC.
		
	By:	 	  

		 	Name:
		 	Title:

 Transition Services Agreement 

H&S to Fortune Brands

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]